Počet záznamov: 1
A Phase III, randomized, double-blind, placebo-controlled trial of pegfilgrastim in patients receiving first-line FOLFOX/Bevacizumab or FOLFIRI/Bevacizumab for locally advance or metastatic colorectal cancer: final results of the pegfilgrastim and anti-VEGF evaluation study (PAVES)
- A Phase III, randomized, double-blind, placebo-controlled trial of pegfilgrastim in patients receiving first-line FOLFOX/Bevacizumab or FOLFIRI/Bevacizumab for locally advance or metastatic colorectal cancer: final results of the pegfilgrastim and anti-VEGF evaluation study (PAVES) / Salek T. . Onkológia. - ISSN 1336-8176 . - Roč. 12, č. 5 (2017), s. 379
- C 3069
článok
Počet záznamov: 1